Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 15.4 USD 0.46% Market Closed
Market Cap: 828.7m USD
Have any thoughts about
Prothena Corporation PLC?
Write Note

Prothena Corporation PLC
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prothena Corporation PLC
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Prothena Corporation PLC
NASDAQ:PRTA
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alkermes Plc
NASDAQ:ALKS
Other
-$306.7m
CAGR 3-Years
-182%
CAGR 5-Years
-88%
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
Other
-$1.6m
CAGR 3-Years
44%
CAGR 5-Years
32%
CAGR 10-Years
-10%
No Stocks Found

Prothena Corporation PLC
Glance View

Market Cap
828.7m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
36.55 USD
Undervaluation 58%
Intrinsic Value
Price

See Also

Back to Top